Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer

Journal of Biological Chemistry

Volumn 287, Issue 11, 2012, Pages 8048-8059

  Lai, Andrea Z ^a,b   Durrant, Michael ^b   Zuo, Dongmei ^a   Ratcliffe, Colin D H ^a,b   Park, Morag ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PROCESS; E3 LIGASE; GASTRIC CANCER CELL LINES; GASTRIC CANCERS; KINASE ACTIVATION; KINASE ACTIVITY; LACTACYSTIN; PROTEASOME INHIBITORS; RECEPTOR SIGNALING; RECEPTOR TYROSINE KINASE; SIGNAL ATTENUATION; SIGNAL DURATION; UBIQUITINATION;

AMINO ACIDS; CELL CULTURE; CHEMICAL ACTIVATION; DISEASES; SIGNAL PROCESSING;

ENZYMES;

CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LACTACYSTIN; MET KINASE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CANCER;

CELL LINE, TUMOR; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TRANSPORT; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-CBL; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; UBIQUITINATION;

EID: 84858025728     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.339820     Document Type: Article

References (57)

1. Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., and Vande Woude, G. F. (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311, 29-33 (Pubitemid 14065275)
2. Park, M., Dean, M., Cooper, C. S., Schmidt, M., O'Brien, S. J., Blair, D. G., and Vande Woude, G. F. (1986) Mechanism of Met oncogene activation. Cell 45, 895-904 (Pubitemid 16083694)
3. Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M., Kmiecik, T. E., Vande Woude, G. F., and Aaronson, S. A. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804 (Pubitemid 21926175)
4. Naldini, L., Weidner, K. M., Vigna, E., Gaudino, G., Bardelli, A., Ponzetto, C., Narsimhan, R. P., Hartmann, G., Zarnegar, R., Michalopoulos, G. K., et al. (1991) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 10, 2867-2878 (Pubitemid 21905304)
5. Fournier, T. M., Kamikura, D., Teng, K., and Park, M. (1996) Branching tubulogenesis but not scatter of Madin-Darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase. J. Biol. Chem. 271, 22211-22217 (Pubitemid 26303855)
6. Vasyutina, E., Stebler, J., Brand-Saberi, B., Schulz, S., Raz, E., and Birchmeier, C. (2005) CXCR4 and Gab1 cooperate to control the development of migrating muscle progenitor cells. Genes Dev. 19, 2187-2198 (Pubitemid 41330320)
7. Huh, C. G., Factor, V. M., Sánchez, A., Uchida, K., Conner, E. A., and Thorgeirsson, S. S. (2004) Hepatocyte growth factor/c-Met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. U.S.A. 101, 4477-4482 (Pubitemid 38437436)
8. Borowiak, M., Garratt, A. N., Wüstefeld, T., Strehle, M., Trautwein, C., and Birchmeier, C. (2004) Met provides essential signals for liver regeneration. Proc. Natl. Acad. Sci. U.S.A. 101, 10608-10613 (Pubitemid 38955789)
9. Peschard, P., and Park, M. (2007) From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 26, 1276-1285 (Pubitemid 46328462)
10. Smolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., Okimoto, R. A., Bell, D. W., Sgroi, D. C., Christensen, J. G., Settleman, J., and Haber, D. A. (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. U.S.A. 103, 2316-2321
11. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C. M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., and Jänne, P. A. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (Pubitemid 46799492)
12. Okuda, K., Sasaki, H., Yukiue, H., Yano, M., and Fujii, Y. (2008) Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 99, 2280-2285
13. Cappuzzo, F., Jänne, P. A., Skokan, M., Finocchiaro, G., Rossi, E., Ligorio, C., Zucali, P. A., Terracciano, L., Toschi, L., Roncalli, M., Destro, A., Incarbone, M., Alloisio, M., Santoro, A., and Varella-Garcia, M. (2009) MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol. 20, 298-304
14. (2008) Nature 455, 1061-1068
15. Peschard, P., and Park, M. (2003) Escape from Cbl-mediated down-regulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3, 519-523 (Pubitemid 36808646)
16. Langdon, W. Y., Hartley, J. W., Klinken, S. P., Ruscetti, S. K., and Morse, H. C., 3rd (1989) v-cbl, an oncogene from a dual recombinant murine retrovirus that induces early B-lineage lymphomas. Proc. Natl. Acad. Sci. U.S.A. 86, 1168-1172 (Pubitemid 19061515)
17. Keane, M. M., Rivero-Lezcano, O. M., Mitchell, J. A., Robbins, K. C., and Lipkowitz, S. (1995) Cloning and characterization of cbl-b: a SH3-binding protein with homology to the c-cbl proto-oncogene. Oncogene 10, 2367-2377
18. Keane, M. M., Ettenberg, S. A., Nau, M. M., Banerjee, P., Cuello, M., Penninger, J., and Lipkowitz, S. (1999) Cbl-3: a new mammalian Cbl family protein. Oncogene 18, 3365-3375 (Pubitemid 29286982)
19. Thien, C. B., and Langdon, W. Y. (2001) Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2, 294-307
20. Bartkiewicz, M., Houghton, A., and Baron, R. (1999) Leucine zipper-mediated homodimerization of the adaptor protein c-Cbl. A role in c-Cbl's tyrosine phosphorylation and its association with epidermal growth factor receptor. J. Biol. Chem. 274, 30887-30895
21. Kozlov, G., Peschard, P., Zimmerman, B., Lin, T., Moldoveanu, T., Mansur-Azzam, N., Gehring, K., and Park, M. (2007) Structural basis for UBA-mediated dimerization of c-Cbl ubiquitin ligase. J. Biol. Chem. 282, 27547-27555 (Pubitemid 47501924)
22. Peschard, P., Kozlov, G., Lin, T., Mirza, I. A., Berghuis, A. M., Lipkowitz, S., Park, M., and Gehring, K. (2007) Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b. Mol. Cell 27, 474-485 (Pubitemid 47126940)
23. Thien, C. B., and Langdon, W. Y. (2005) c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. Biochem. J. 391, 153-166 (Pubitemid 41532411)
24. Naramura, M., Jang, I. K., Kole, H., Huang, F., Haines, D., and Gu, H. (2002) c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat. Immunol. 3, 1192-1199 (Pubitemid 35469704)
25. Purev, E., Neff, L., Horne, W. C., and Baron, R. (2009) c-Cbl and Cbl-b act redundantly to protect osteoclasts from apoptosis and to displace HDAC6 from beta-tubulin, stabilizing microtubules, and podosomes. Mol. Biol. Cell 20, 4021-4030
26. Pennock, S., and Wang, Z. (2008) A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor down-regulation. Mol. Cell. Biol. 28, 3020-3037 (Pubitemid 351556533)
27. Peschard, P., Fournier, T. M., Lamorte, L., Naujokas, M. A., Band, H., Langdon, W. Y., and Park, M. (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995-1004 (Pubitemid 34031802)
28. Tsygankov, A. Y., Teckchandani, A. M., Feshchenko, E. A., and Swaminathan, G. (2001) Beyond the RING: CBL proteins as multivalent adapters. Oncogene 20, 6382-6402 (Pubitemid 32977846)
29. Abella, J. V., Peschard, P., Naujokas, M. A., Lin, T., Saucier, C., Urbé, S., and Park, M. (2005) Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol. Cell. Biol. 25, 9632-9645 (Pubitemid 41507861)
30. Hammond, D. E., Urbé, S., Vande Woude, G. F., and Clague, M. J. (2001) Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 20, 2761-2770 (Pubitemid 32549833)
31. Mak, H. H., Peschard, P., Lin, T., Naujokas, M. A., Zuo, D., and Park, M. (2007) Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. Oncogene 26, 7213-7221 (Pubitemid 350085315)
32. Onozato, R., Kosaka, T., Kuwano, H., Sekido, Y., Yatabe, Y., and Mitsudomi, T. (2009) Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J. Thorac. Oncol. 4, 5-11
33. Kong-Beltran, M., Seshagiri, S., Zha, J., Zhu, W., Bhawe, K., Mendoza, N., Holcomb, T., Pujara, K., Stinson, J., Fu, L., Severin, C., Rangell, L., Schwall, R., Amler, L., Wickramasinghe, D., and Yauch, R. (2006) Somatic mutations lead to an oncogenic deletion of Met in lung cancer. Cancer Res. 66, 283-289 (Pubitemid 43166034)
34. Ma, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M. S., Nallasura, V., Fox, E. A., Hansen, M., Schaefer, E., Naoki, K., Lader, A., Richards, W., Sugarbaker, D., Husain, A. N., Christensen, J. G., and Salgia, R. (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65, 1479-1488 (Pubitemid 40270177)
35. Asaoka, Y., Tada, M., Ikenoue, T., Seto, M., Imai, M., Miyabayashi, K., Yamamoto, K., Yamamoto, S., Kudo, Y., Mohri, D., Isomura, Y., Ijichi, H., Tateishi, K., Kanai, F., Ogawa, S., Omata, M., and Koike, K. (2010) Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem. Biophys. Res. Commun. 394, 1042-1046
36. Rodrigues, G. A., Naujokas, M. A., and Park, M. (1991) Alternative splicing generates isoforms of the Met receptor tyrosine kinase which undergo differential processing. Mol. Cell. Biol. 11, 2962-2970 (Pubitemid 21895681)
37. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., and Speleman, F. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034
38. Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P., Chan, E., Le, P., Chen, J., Wang, X., Ruslim, L., Blake, R., Lipson, K. E., Ramphal, J., Do, S., Cui, J. J., Cherrington, J. M., and Mendel, D. B. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63, 7345-7355 (Pubitemid 37413476)
39. Bao, J., Gur, G., and Yarden, Y. (2003) Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proc. Natl. Acad. Sci. U.S.A. 100, 2438-2443 (Pubitemid 36297517)
40. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G., and Comoglio, P. M. (1994)Amultifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261-271 (Pubitemid 24138623)
41. Ettenberg, S. A., Magnifico, A., Cuello, M., Nau, M. M., Rubinstein, Y. R., Yarden, Y., Weissman, A. M., and Lipkowitz, S. (2001) Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J. Biol. Chem. 276, 27677-27684
42. Swaminathan, G., and Tsygankov, A. Y. (2006) The Cbl family proteins: ring leaders in regulation of cell signaling. J. Cell. Physiol. 209, 21-43 (Pubitemid 44318665)
43. Lai, A. Z., Abella, J. V., and Park, M. (2009) Cross-talk in Met receptor oncogenesis. Trends Cell Biol. 19, 542-551
44. Ryan, P. E., Davies, G. C., Nau, M. M., and Lipkowitz, S. (2006) Regulating the regulator: negative regulation of Cbl ubiquitin ligases. Trends Biochem. Sci. 31, 79-88 (Pubitemid 43221840)
45. Feshchenko, E. A., Langdon, W. Y., and Tsygankov, A. Y. (1998) Fyn, Yes, and Syk phosphorylation sites in c-Cbl map to the same tyrosine residues that become phosphorylated in activated T cells. J. Biol. Chem. 273, 8323-8331 (Pubitemid 28168891)
46. Wang, Y., Yeung, Y. G., and Stanley, E. R. (1999) CSF-1 stimulated multiubiquitination of the CSF-1 receptor and of Cbl follows their tyrosine phosphorylation and association with other signaling proteins. J. Cell. Biochem. 72, 119-134 (Pubitemid 28541487)
47. Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., Lipkowitz, S., and Yarden, Y. (1999) Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 4, 1029-1040 (Pubitemid 30054908)
48. Kassenbrock, C. K., and Anderson, S. M. (2004) Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations. J. Biol. Chem. 279, 28017-28027 (Pubitemid 38900072)
49. Bisson, S. A., Ujack, E. E., and Robbins, S. M. (2002) Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line. Oncogene 21, 3677-3687 (Pubitemid 34620531)
50. Kales, S. C., Ryan, P. E., Nau, M. M., and Lipkowitz, S. (2010) Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res. 70, 4789-4794
51. Makishima, H., Cazzolli, H., Szpurka, H., Dunbar, A., Tiu, R., Huh, J., Muramatsu, H., O'Keefe, C., Hsi, E., Paquette, R. L., Kojima, S., List, A. F., Sekeres, M. A., McDevitt, M. A., and Maciejewski, J. P. (2009) Mutations of e3 ubiquitin ligase Cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J. Clin. Oncol. 27, 6109-6116
52. Tan, Y. H., Krishnaswamy, S., Nandi, S., Kanteti, R., Vora, S., Onel, K., Hasina, R., Lo, F. Y., El-Hashani, E., Cervantes, G., Robinson, M., Hsu, H. S., Kales, S. C., Lipkowitz, S., Karrison, T., Sattler, M., Vokes, E. E., Wang, Y. C., and Salgia, R. (2010) CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One 5, e8972
53. Naramura, M., Nadeau, S., Mohapatra, B., Ahmad, G., Mukhopadhyay, C., Sattler, M., Raja, S. M., Natarajan, A., Band, V., and Band, H. (2011) Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget 2, 245-250
54. McLean, L. A., Gathmann, I., Capdeville, R., Polymeropoulos, M. H., and Dressman, M. (2004) Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin. Cancer Res. 10, 155-165 (Pubitemid 38114174)
55. Rodrigues, G. A., and Park, M. (1993) Dimerization mediated through a leucine zipper activates the oncogenic potential of the Met receptor tyrosine kinase. Mol. Cell. Biol. 13, 6711-6722 (Pubitemid 23321125)
56. Ponzo, M. G., Lesurf, R., Petkiewicz, S., O'Malley, F. P., Pinnaduwage, D., Andrulis, I. L., Bull, S. B., Chughtai, N., Zuo, D., Souleimanova, M., Germain, D., Omeroglu, A., Cardiff, R. D., Hallett, M., and Park, M. (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc. Natl. Acad. Sci. U.S.A. 106, 12903-12908
57. Lo, F. Y., Tan, Y. H., Cheng, H. C., Salgia, R., and Wang, Y. C. (2011) An E3 ubiquitin ligase, c-Cbl: a new therapeutic target of lung cancer. Cancer 117, 5344-5350